Tim Cortese

SHR-1701, a PD-L1 and TGF-ß targeting agent, reduced chemotherapy-induced myelosuppression in patients with HER2-negative gastric/GEJ adenocarcinoma.

The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS syndrome, with or without MDS.

The phase 2 LODEFI study showed that low-dose deferasirox achieved transfusion independence and was well-tolerated in low-risk anemic MDS.